Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11-1F4-CAR phagocyte
- Development stage
- Preclinical
- Lead developer
- Columbia University Irving Medical Center
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
11-1F4-CAR phagocyte (also referred to as 11-1F4-CAR macrophage) is a first-in-class, preclinical-stage chimeric antigen receptor (CAR) cell therapy being developed by Columbia University Irving Medical Center for the treatment of immunoglobulin light chain (AL) amyloidosis. The therapy consists of human CD34+ hematopoietic stem cell-derived phagocytes genetically engineered via lentiviral transduction to express a CAR construct containing an extracellular single-chain variable fragment (scFv) derived from the amyloid-fibril-specific monoclonal antibody 11-1F4 (anselamimab) and an intracellular Fc receptor gamma (FcRγ) signaling domain. By directly targeting amyloid deposits, 11-1F4-CAR phagocytes bypass serum IgG Fc receptor competition (which can impair antibody-dependent phagocytosis in patients receiving anti-CD38 therapies) to enhance and accelerate the clearance of λ6 Wil and κ4 Len amyloid fibrils.
- Other names
- 11-1F4 CAR macrophage11-1F4-CAR macrophage
02
Targets
FCER1G (Fc epsilon receptor I gamma subunit)
Beyond the preview
Go deeper on 11-1F4-CAR phagocyte.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 11-1F4-CAR phagocyte.